about
Vancomycin enhancement of experimental tobramycin nephrotoxicityVancomycin- and erythromycin-induced hearing loss in humansLack of effect of vancomycin and gentamicin on auditory function in guinea pigsMycobacterium avium-M. intracellulare and Acquired Immunodeficiency Syndrome.Effect of vancomycin-coated tympanostomy tubes on methicillin-resistant Staphylococcus aureus biofilm formation: in vitro study.Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters.Intrarenal distribution of vancomycin in endotoxemic ratsIn vitro activities of ramoplanin, selected glycopeptides, fluoroquinolones, and other antibiotics against clinical bloodstream isolates of gram-positive cocci.Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK.Subcellular localization of tobramycin and vancomycin given alone and in combination in proximal tubular cells, determined by immunogold labeling.Gene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates.Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review.Antimicrobial therapy for the elderly patient.Vancomycin therapeutic drug monitoring: is it necessary?Vancomycin Prophylaxis for Total Joint Arthroplasty: Incorrectly Dosed and Has a Higher Rate of Periprosthetic Infection Than Cefazolin.Vancomycin ototoxicity and nephrotoxicity. A review.Vancomycin: an update.Teicoplanin or vancomycin in the treatment of gram-positive infections?A closer look at vancomycin, teicoplanin, and antimicrobial resistance.Adverse effects of vancomycin in children: a review of 22 cases.Mississippi mud in the 1990s: risks and outcomes of vancomycin-associated toxicity in general oncology practice.Exchange transfusion and multidose activated charcoal following vancomycin overdose.Establishment of norvancomycin fluorescence polarization immunoassay for therapeutic drug monitoring.
P2860
Q28362084-F51AB0FB-5B56-4623-AACF-5DFE73C8C9C0Q30502734-271BA94C-1222-4BD3-9859-895BA2A9B715Q30532055-935296B1-3975-4EB6-A538-85A8FD69CD32Q33741753-6FBB4A61-27EC-450D-AD93-A804E19F2BF6Q34091485-F1F280EC-BF64-45C8-8F17-898D03FC69CBQ35341106-7A87367E-64F5-4354-B78F-847E2DD095A5Q35350008-B3AF68AD-3427-40BC-B9D5-87168C9E0F64Q35812860-5C73BFC5-3A00-4104-AB05-4798E7095E82Q36409465-73EEA935-F472-40A4-B9DB-62D74D21A5F3Q36757810-62B0E14E-C5F3-4E34-899C-B94B056CAE68Q37089738-45295DAF-9D0E-46EB-ABAD-D347667590AAQ37992997-C36ACECA-5132-40DF-A3CF-6BCC118B49B8Q38006505-C7664181-591B-4381-B5F1-18458E2F0CFAQ38566835-D7037CAB-9E3A-47E4-AB72-3913DB3B930EQ38841252-C50CB771-06FD-4B6B-879A-FF848F3221C1Q39542494-8225B23C-4AE6-4CC7-97D9-3E2E5B7FDE47Q39746652-3E6B3D8B-941C-4DF3-9C98-7769D6FF49D0Q40541603-BF3344F5-2B97-4E94-BBCB-86C3E3942233Q41646436-ECD1B34A-0373-49A7-9B27-B1DCE78FD7EEQ41734564-1728BEBB-B9C8-40A8-80B1-E65C8C0E5C3EQ42537120-305DCA59-2A73-47E9-B386-D0D6D3C6C915Q50540715-90502D1A-8544-49C3-AE2A-3099FBA7B4CBQ51506580-D5DABD56-6250-430B-8E13-F6554E2C2704
P2860
description
1985 nî lūn-bûn
@nan
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
1985年论文
@zh
1985年论文
@zh-cn
name
Vancomycin toxicity: a prospective study.
@en
Vancomycin toxicity: a prospective study.
@nl
type
label
Vancomycin toxicity: a prospective study.
@en
Vancomycin toxicity: a prospective study.
@nl
prefLabel
Vancomycin toxicity: a prospective study.
@en
Vancomycin toxicity: a prospective study.
@nl
P2093
P356
P1476
Vancomycin toxicity: a prospective study.
@en
P2093
P304
P356
10.1093/JAC/15.6.773
P407
P577
1985-06-01T00:00:00Z